Sign in

    Samantha Schaeffer

    Biotech Equity Research Associate at Cantor Fitzgerald

    Samantha Schaeffer is a Biotech Equity Research Associate at Cantor Fitzgerald, specializing in biotechnology sector analysis with a focus on clinical-stage therapeutics and rare disease companies. She has participated in earnings calls and covered companies such as Alector Inc and Arcturus Therapeutics Holdings Inc, providing research insights and engaging with management during quarterly performance reviews. Schaeffer began her career at Cantor Fitzgerald and has established herself as a rising analyst within the healthcare and biotech research community, though detailed performance metrics and previous firm experience remain limited. She supports the research team in providing in-depth industry analysis and is expected to hold relevant securities licenses as required for her role.

    Samantha Schaeffer's questions to Alector (ALEC) leadership

    Samantha Schaeffer's questions to Alector (ALEC) leadership • Q2 2025

    Question

    Samantha Schaeffer of Cantor Fitzgerald asked if the company expects to see signs of disease progression or a treatment effect in the 16 asymptomatic patients enrolled in INFRONT3 within the 96-week trial period. She also inquired about the patient rollover rate into the open-label extension study.

    Answer

    CMO Giacomo Salvadore noted that the asymptomatic cohort is part of a sensitivity analysis and could not comment on expected outcomes as the trial is blinded. CEO Arnon Rosenthal added these patients were selected based on high neurofilament levels, which suggests a risk of conversion. Regarding the open-label extension, Giacomo Salvadore said the company is satisfied with the rollover rate but has not disclosed specific numbers.

    Ask Fintool Equity Research AI

    Samantha Schaeffer's questions to Arcturus Therapeutics Holdings (ARCT) leadership

    Samantha Schaeffer's questions to Arcturus Therapeutics Holdings (ARCT) leadership • Q1 2025

    Question

    Samantha Schaeffer, on for Pete Stavropoulos at Cantor Fitzgerald, asked about the potential for ARCT-032 to remodel or normalize the lungs over time and what other measurements beyond FEV, such as quality of life, are being used to build conviction.

    Answer

    President and CEO Joseph Payne expressed optimism that ARCT-032 could lead to lung regeneration over time, as the topically administered agent could allow for steady improvement as the lung heals. He confirmed that in addition to FEV, a validated CF quality of life questionnaire is being used to complement the primary endpoint data, although the FDA has indicated FEV improvement is sufficient to advance the program.

    Ask Fintool Equity Research AI